MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ELUT Stock dropped -3.13% Today — RQD Quant Desk Flash
$0.81 -3.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.80
Elutia Inc. (Class A) (ELUT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $36.0M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.80 (-0.75%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELUT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ELUT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (35% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)
FRED Regime × Technicals: 35% of 52W Range • RSI-14 at 53.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.82-3.7% Next Q
42
Q2 (-2Q)Grade E$0.79+6.3% Next Q
39
Q3 (-1Q)Grade E$0.84-3.6% Next Q
37
CurrentGrade E$0.81-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ELUT Turnaround Squeeze
While ELUT currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.85) forces dealer call-delta covering toward $1.46.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELUT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ELUT Stock dropped -3.13% Today — RQD Quant Desk Flash
Elutia Inc. (Class A) (ELUT) dropped -3.13% to $0.81, trading at 35% of its 52-week range ($0.5 – $1.39). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 35% of its 52-week range ($0.5 – $1.39) with RSI-14 at 53.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.81 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 53.7% gross margin and $0 annual free cash flow.
Live ELUT Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELUT)
- ✓Walkthrough of ELUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ELUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.59%▼ DESCENDING CHANNEL
2026-10-30O $0.81H $0.86L $0.80C $0.81VOL 138.3K
RES: $0.89SUP: $0.62SMA50: $0.83SMA200: $0.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ELUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ELUT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ELUT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELUT)
Health Care Rank #850 of 1016
⚔️ EXOZ vs ELUT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ELUT vs. EXOZ, ESLA, ALGS, MGX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Elutia Inc. (Class A) (ELUT) ranks #850 by composite RQD confidence (34/100, grade E) and #786 by equity capitalization ($36.0M). Within this direct 5-issuer industry benchmark cohort, ELUT leads on earnings valuation at N/A trailing P/E, while ELUT leads on capital efficiency and profitability with -35.0% ROIC and 53.7% gross margin. ESLA currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with ELUT at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELUT
ACTIVE
Elutia Inc. (Class A) | E | 34/100 | — | 53.7% | -35.0% | -3.13% | $36.0M | Benchmark Subject |
| EXOZ eXoZymes Inc. | D- | 36/100 | — | — | -35.0% | -2.72% | $38.2M | /exoz-vs-elut → |
| ESLA Estrella Immunopharma Inc. | D- | 41/100 | — | — | -35.0% | -11.32% | $31.7M | /esla-vs-elut → |
| ALGS Aligos Therapeutics Inc. | E | 26/100 | — | — | -35.0% | -2.71% | $31.4M | /algs-vs-elut → |
| MGX Metagenomi Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | +1.03% | $31.4M | /mgx-vs-elut → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001708527In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported GAAP revenue of $12.3M (-15.0% vs. FY2024 revenue of $14.5M ) , GAAP net income of $53.4M, operating cash flow of -$44.8M, and free cash flow of -$46.7M (-100.3% YoY). On the balance sheet, ELUT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $12.3M | $53.4M | -$44.8M | -$46.7M | $62.4M | — |
| FY2024 (FY) | 2024-12-31 | $14.5M | -$53.9M | -$22.7M | -$23.3M | $36.1M | $22.6M |
| FY2023 (FY) | 2023-12-31 | $0 | -$37.7M | -$21.8M | -$21.8M | — | — |
3. ELUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.81 (-3.13% 1D, market cap $36.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ELUT ranks #850 in composite RQD confidence.
How does ELUT compare to EXOZ and ESLA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, EXOZ (eXoZymes Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $38.2M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ELUT?
Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ELUT trading relative to its 50-day, 200-day, and 52-week technical levels?
ELUT last traded at $0.81 (-3.13% on volume of 56,045 shares), positioning the stock -2.41% below its 50-day simple moving average ($0.83) and -16.49% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.50 to $1.39, ELUT sits at the 34.8% percentile with a 14-day RSI of 53.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.91).
ELUT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ELUT stock moving today?
Why ELUT Stock dropped -3.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.